Estate Planning Dilemma Can Family Cash Out CDs of Father in Hospice Care UK Student Loans Inquiry Draws Over 52000 Responses Highlighting Massive Scale of Frustration and Upset Jim Cramers Vote of Confidence on Intuit INTU Preceded a Steep Decline Micron Technology Shares Eye Best Monthly Performance Since 1987 Analysts Flag Value Opportunity BMO Capital Reaffirms Outperform Rating on SAP After Sapphire 2026 Conference Price Target Set at 200 Tui Ends Sponsorship of Married at Age After Sexual Misconduct Allegations TS Q1 2026 Earnings EPS Surpasses Estimates But Stock Slips Amid Uncertain Revenue Outlook XXII Q1 2026 Earnings Significant EPS Miss Highlights Continued Challenges LMT Q1 2026 Earnings Earnings Miss Stock Rises Amid Defense Sector Optimism LLYVK Q4 2025 Earnings EPS Nearly Matches Estimates but Surprise Miss and Flat Revenue Weigh on Sentiment Hyliion Holdings Corp HYLN Q1 2026 Earnings Narrower Loss Fuels 42 Rally SXI Q1 2026 Earnings Modest EPS Miss Amidst Solid Operational Performance CollPlant Biotechnologies CLGN Slides 667 as Selling Pressure Mounts Rapport Therapeutics RAPP Holds Steady as Minor Decline Tests Key Support Levels Summit Midstream Corporation SMC Faces Resistance After 36 Decline New Era Energy Digital Inc NUAI Rallies 4 as Stock Approaches Key Resistance AgEagle Aerial Systems UAVS Surges 5 as Shares Test Key Resistance at 107 EU Imposes 230M Fine on Temu Over Alleged Illegal Product Sales AAUC Q1 2026 Earnings EPS Surges 82 Above Estimates Exceeding Expectations Sotherly Hotels Preferred Stock SOHOB Plunges Over 8 as Support Levels Tested ATT Q1 2026 Earnings EPS Slightly Beats Estimates Stock Edges Lower Ainos Inc AIMD Q1 2025 Earnings Continued Adjusted Losses Amid Strategic Pivot SVRA Q1 2026 Earnings Wider Loss Amid Continued Pipeline Development Willis Lease Finance Corporation WLFC Q1 2026 Earnings Substantial EPS Surprise Highlights Strong Operating Performance ENSG Q1 2026 Earnings Slight EPS Miss Amidst Steady Operations DMAC Q1 2026 Earnings WiderthanExpected Loss as Clinical Development Costs Persist ABUS Q1 2026 Earnings EPS Misses Estimates as PreRevenue Biotech Advances Pipeline